It's brand name is Aciphex, it's a PPI ( proton pump inhibitor) used to keep the pH of your stomach lower, like pantoprazole ( protonix). It is commonly used in patients with heartburn.
Pantoprazole and rabeprazole are both proton pump inhibitors used to reduce stomach acid production. They have different chemical structures and slightly different mechanisms of action, but they are both effective in treating conditions such as acid reflux and ulcers. The choice between the two drugs is typically based on individual patient response and tolerability.
Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active, benign gastric ulcers. Methods: In this randomized, double-blind, multicentrestudy, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers. Two hundred and twenty-seven patients with active benign gastric ulcer were randomized to receive either rabeprazole 20 mg (nà 113) or omeprazole 20 mg (nà 114) once daily for 3 or 6 weeks, with healing monitored by endoscopy. Results : After 3 weeks, complete healing (ITT analysis) was documented in 58% of patients given rabeprazole and 61% in patients given omeprazole (N.S.). After 6 weeks the healing rates were identical in both groups at 91%. Rabeprazole-treated patients had numerically greater symptom relief at all 12 points of comparison. The differences significantly favoured rabeprazole at week 3 for daytime pain improvement (P= 0.023) and at week 6 for pain frequency (P= 0.006) and complete resolution of night pain (P= 0.022). Both drugs were well-tolerated over the 6-week treatment course. Mean changes from baseline to end-point in fasting serumgastrin were comparable. No significant differences in laboratory parameters were seen. Conclusion: In this study, rabeprazole produced healing rates comparable to omeprazole at weeks 3 and 6, but provided more consistent and occasionally significantly superior symptom improvement. Both treatments were well-tolerated.
The dissolution medium commonly used for testing Rabeprazole enteric-coated tablets is acidic buffer solutions such as Simulated Gastric Fluid (SGF) with a pH of 1.2 for the initial stage and then transitioning to Simulated Intestinal Fluid (SIF) at pH 6.8 to simulate conditions in the stomach and intestines, respectively. These buffers help to mimic the pH conditions the tablet will encounter in the gastrointestinal tract and assess its release characteristics.
sodium chlorateNaClO3 = Sodium Chlorate
Sodium fluoride is an ionic compound with the formula NaF.
ciphex Warnings/Precautions Patients with liver disease are strongly advised to see their doctor prior to taking Aciphex. You may be given dosage adjustments or you may need to undergo special monitoring during the treatment period of Aciphex. In some cases, active ingredient in ACIPHEX (rabeprazole sodium) Delayed-Release Tablets and in ACIPHEX Sprinkle (rabeprazole sodium) Delayed-Release Capsules is rabeprazole sodium, which is a proton pump inhibitor. It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.42. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol. Nonetheless, see your doctor for advice prior to taking Aciphex. Its also important that you will not do things or eat foods that might cause the effect of Aciphex to slow down.
GERD
Rabeprazole is the only ppi which doesn't require cyp2c19 to metabolize in the body.so no drug interaction with other drugs which are taken with rabeprazole.but pantoprazole required same that why rabeprazole is superior compare to pantoprazole
oxidation
Yes, rabeprazole is sensitive to light. It should be stored in its original packaging or container, away from light and moisture, to maintain its stability and effectiveness.
Rabeprazole is a selective and irreversible proton pump inhibitor. Rabeprazole suppresses gastric acid secretion by specific inhibition of the hydrogen-potassium adenosine triphosphatase (H+, K+-ATPase) enzyme system found at the secretory surface of parietal cells. It inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen. Since the H+, K +-ATPase enzyme system is regarded as the acid (proton) pump of the gastric mucosa, rabeprazole is known as a gastric acid pump inhibitor. Rabeprazole does not have anticholinergic or histamine H2-receptor antagonist properties
Pantoprazole and rabeprazole are both proton pump inhibitors used to reduce stomach acid production. They have different chemical structures and slightly different mechanisms of action, but they are both effective in treating conditions such as acid reflux and ulcers. The choice between the two drugs is typically based on individual patient response and tolerability.
Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active, benign gastric ulcers. Methods: In this randomized, double-blind, multicentrestudy, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers. Two hundred and twenty-seven patients with active benign gastric ulcer were randomized to receive either rabeprazole 20 mg (nà 113) or omeprazole 20 mg (nà 114) once daily for 3 or 6 weeks, with healing monitored by endoscopy. Results : After 3 weeks, complete healing (ITT analysis) was documented in 58% of patients given rabeprazole and 61% in patients given omeprazole (N.S.). After 6 weeks the healing rates were identical in both groups at 91%. Rabeprazole-treated patients had numerically greater symptom relief at all 12 points of comparison. The differences significantly favoured rabeprazole at week 3 for daytime pain improvement (P= 0.023) and at week 6 for pain frequency (P= 0.006) and complete resolution of night pain (P= 0.022). Both drugs were well-tolerated over the 6-week treatment course. Mean changes from baseline to end-point in fasting serumgastrin were comparable. No significant differences in laboratory parameters were seen. Conclusion: In this study, rabeprazole produced healing rates comparable to omeprazole at weeks 3 and 6, but provided more consistent and occasionally significantly superior symptom improvement. Both treatments were well-tolerated.
Yes, I'm taking both right now and it was recommended by my pharmacist.
Rabeprazole is a type of drug made to treat stomach conditions such as ulcers that is available over-the-counter. People interested in purchasing some should try their local pharmacy or online stores such as Quality Generics and International Drug Mart.
Omeprazole (Prilosec)Lanoprazole (Prevacid)Esomeprazole (Nexium)Pantoprazole (Protonix)Rabeprazole (Acifex)
The dissolution medium commonly used for testing Rabeprazole enteric-coated tablets is acidic buffer solutions such as Simulated Gastric Fluid (SGF) with a pH of 1.2 for the initial stage and then transitioning to Simulated Intestinal Fluid (SIF) at pH 6.8 to simulate conditions in the stomach and intestines, respectively. These buffers help to mimic the pH conditions the tablet will encounter in the gastrointestinal tract and assess its release characteristics.